Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — Januar 2026

Biotek-snakken — Januar 2026

Planlagt Fastgjort Låst Flyttet Biotek-snakken
66 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #31

    Forstår ikke helt hvorfor PD-L1 negativ er bedrre end positiv - troede det ville forholde sig omvendt.

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #32

      For Tevimbra armen er det vel forventet at ORR er på samme niveau, men forventningen vel er at det er duration of response og OS der rykker - det tegner det vel til. Tænker det kan rykke sig til det bedre ved næste interimanalyse.

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #33

        Djævlen ligger altid i detaljerne, så det kræver en nærmere analyse at blive klog på, så håber at tage mig lidt tid til det i weekenden.

        1 Reply Last reply
        0
        • L Offline
          L Offline
          lahn1
          wrote on sidst redigeret af
          #34

          Der er jo ASCO og Jazz presentation idag kl 15.30 https://investor.jazzpharma.com/events/event-details/zanidatamab-herizon-gea-01-investor-webcast

          1 Reply Last reply
          0
          • L Offline
            L Offline
            lahn1
            wrote on sidst redigeret af
            #35

            prøver at forstå PD-L! isuue mha Chatgpt. PD-L1–negative GEA has:
            worse baseline prognosis
            poor response to chemo and IO alone
            lower OS in the control arm
            That means:
            Small absolute improvements translate into very large hazard ratio gains
            HRs look dramatic because the comparator performs badly
            So in PD-L1–negative disease:
            Control arm does poorly
            Triplet arm does “less poorly”
            → HRs look spectacular

            1 Reply Last reply
            0
            • L Offline
              L Offline
              lahn1
              wrote on sidst redigeret af
              #36

              This does not mean:
              zanidatamab + chemo is weak per se
              or that IO is somehow redundant in PD-L1–positive disease
              It means the biology of PD-L1–negative tumors creates more headroom for relative gains. ???

              1 Reply Last reply
              0
              • F Offline
                F Offline
                Fandel
                wrote on sidst redigeret af
                #37

                Godmorgen...

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #38

                  Monte Rosa hentede lidt mere end først oplyst og til fine kurs 24.

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #39

                    Link Preview Image
                    Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

                    BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a public offering price of $24.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 shares of common stock at a public offering price

                    favicon

                    Yahoo Finance (finance.yahoo.com)

                    1 Reply Last reply
                    0
                    • HenrikhotH Offline
                      HenrikhotH Offline
                      Henrikhot
                      wrote on sidst redigeret af
                      #40

                      Egetis Therapeutics Er et interessant valg. De er lidt i samme situation som Hansa Biopharma, der har et lægemiddel godkendt i Eu er har indsendt markedf.godk. 19 dec 25. De vil få en voucher ved godkendelse ca q3-4, der vil hjælpe på økonomien.

                      1 Reply Last reply
                      0
                      • F Offline
                        F Offline
                        Fandel
                        wrote on sidst redigeret af
                        #41

                        Godmorgen...

                        1 Reply Last reply
                        0
                        • L Offline
                          L Offline
                          LP90
                          wrote on sidst redigeret af
                          #42

                          Henrikhot jeg har den i 2 depoter tror du ikke de skal ud og hente mere kapital inden ??? det frygter jeg lidt ?

                          1 Reply Last reply
                          0
                          • HenrikhotH Offline
                            HenrikhotH Offline
                            Henrikhot
                            wrote on sidst redigeret af
                            #43

                            LP90 hvis alt går efter planen vil voucheren hjælpe deres økonomi rigtig meget. Måske de vil udnytte, hvis kursen stiger meget, til at hente peng ved emmision med knap så stor udvanding.Men det ville så være af strategiske årsager.

                            1 Reply Last reply
                            0
                            • L Offline
                              L Offline
                              LP90
                              wrote on sidst redigeret af
                              #44

                              Henrikhot tak 🙂

                              1 Reply Last reply
                              0
                              • M Offline
                                M Offline
                                Mads83
                                wrote on sidst redigeret af
                                #45

                                Curasight - Årets første, bedste nyhed: Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT[®] in High-Grade Gliomas.... / The preliminary dosimetry readout of uTREAT® was in line with expectations and supports to continue with additional GBM patients. Currently more patients are enrolled, and top-line data is expected in Q2 2026. https://news.cision.com/curasight/r/curasight-announces-encouraging-preliminary-data-from-phase-1-

                                1 Reply Last reply
                                0
                                • DarvinD Offline
                                  DarvinD Offline
                                  Darvin
                                  wrote on sidst redigeret af
                                  #46

                                  God (og forventet) nyhed Mads83. Det tegner godt. En start, men med fuld skrue. Tror fortsat på et hurtigt faseforløb frem mod godkendelse. Super effektiv og meget lidt indgribende fjernelse af tumorer.

                                  1 Reply Last reply
                                  0
                                  • L Offline
                                    L Offline
                                    lexus
                                    wrote on sidst redigeret af
                                    #47

                                    Håber det lykkes da det er virkelig frygtelig sygdom.

                                    1 Reply Last reply
                                    0
                                    • L Offline
                                      L Offline
                                      lexus
                                      wrote on sidst redigeret af
                                      #48

                                      Mads83 link viker ikke.

                                      1 Reply Last reply
                                      0
                                      • M Offline
                                        M Offline
                                        Mads83
                                        wrote on sidst redigeret af
                                        #49

                                        @Lexus: tak - jeg prøver igen her: https://news.cision.com/curasight/r/curasight-announces-encouraging-preliminary-data-from-phase-1-trial-evaluating-first-in-class-radiop,c4291355

                                        1 Reply Last reply
                                        0
                                        • M Offline
                                          M Offline
                                          Mads83
                                          wrote on sidst redigeret af
                                          #50

                                          nb, jeg fandt desuden denne artikel (betalt?) for et par dage siden; runder fint casen - og potentialet - op her i forbindelse med JP Morgan Health konferencen: https://briefglance.com/articles/curasights-cancer-platform-takes-center-stage-at-jp-morgan-week?fbclid=IwY2xjawPS9-hleHRuA2FlbQIxMQBzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEeUdwZash-yYGoRL6j3W1Bi7FA9rJPtRbIg2qr1_oHaorynn2gRNu4S0gKuE8_aem_ajOA-UEHPCefwZdvF9dX7A

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper